Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
REVENUES:
Total revenues	$ 30,430	$ 565,464
OPERATING EXPENSES:
Research and development	4,338,974	4,741,130
General and administrative	9,150,568	10,026,627
TOTAL OPERATING EXPENSES	13,489,542	14,767,757
OPERATING LOSS	(13,459,112)	(14,202,293)
Interest and other expense, net	(307,950)	(589,740)
Change in fair value of warrant liability	(1,443,592)	(5,710,362)
TOTAL OTHER EXPENSE	(1,751,542)	(6,300,102)
LOSS BEFORE INCOME TAXES	(15,210,654)	(20,502,395)
Income taxes
NET LOSS	(15,210,654)	(20,502,395)
Deemed dividends		(12,692,308)
Preferred dividends	(1,737,297)	(1,058,498)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (16,947,951)	$ (34,253,201)
Net loss per common share - basic and diluted (in dollars per share)	$ (1.74)	$ (3.84)
Weighted average shares of common shares - basic and diluted (in dollars per share)	$ 9,714,951	$ 8,916,190
Grant [Member]
REVENUES:
Total revenues	$ 30,430	$ 565,464